AMPHAmphastar Pharmaceuticals Inc
$19.51
$1.07
(5.20%)
Pre-Market
EarningsAug 6
Mkt Cap$907.43M
Vol8.00
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 PR Newswire RANCHO CUCAMONGA, Calif., July 29, 2026 RANCHO CUCAMONGA, Calif., July 29, 2026...
PR Newswire
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
Zacks
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
Zacks
New Strong Sell Stocks for June 23rd
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Zacks
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty...
Yahoo! Finance: News
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -40.28% and +0.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been given a consensus rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and tw...
MarketBeat
<
1
2
>
Advertisement|Remove ads.
LMND2
6
NBIS13
20
SOFI7
10Advertisement|Remove ads.